Literature DB >> 21178016

CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells.

Mary K O'Reilly1, Hua Tian, James C Paulson.   

Abstract

CD22 is a member of the sialic acid-binding Ig-like lectin (Siglec) family that is known to be a regulator of B cell signaling. Its B cell-specific expression makes it an attractive target for immunotoxin-mediated B cell depletion therapy for the treatment of B cell lymphomas and autoimmune diseases. Although CD22 is well documented to be an endocytic receptor, it is believed that after internalization, it is targeted for degradation. We show in this study that CD22 is instead constitutively recycled to the cell surface. We also find that glycan ligand-based cargo is released from CD22 and accumulates intracellularly as CD22 recycles between the cell surface and endosomal compartments. In contrast, Abs to CD22 do not accumulate but remain bound to CD22 and recycle to the cell surface. The results have implications for development of agents that target CD22 as an endocytic receptor for delivery of cytotoxic cargo to B cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21178016      PMCID: PMC3024466          DOI: 10.4049/jimmunol.1003005

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  63 in total

1.  Selective internalization of monoclonal antibodies by B-cell chronic lymphocytic leukaemia cells.

Authors:  Thomas Sieber; Dagmar Schoeler; Frauke Ringel; Maria Pascu; Folke Schriever
Journal:  Br J Haematol       Date:  2003-05       Impact factor: 6.998

2.  Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.

Authors:  R J Kreitman; I Margulies; M Stetler-Stevenson; Q C Wang; D J FitzGerald; I Pastan
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

3.  CD22 regulates B cell receptor-mediated signals via two domains that independently recruit Grb2 and SHP-1.

Authors:  K L Otipoby; K E Draves; E A Clark
Journal:  J Biol Chem       Date:  2001-09-10       Impact factor: 5.157

4.  Lipid rafts unite signaling cascades with clathrin to regulate BCR internalization.

Authors:  Angela Stoddart; Michelle L Dykstra; Bruce K Brown; Wenxia Song; Susan K Pierce; Frances M Brodsky
Journal:  Immunity       Date:  2002-10       Impact factor: 31.745

5.  Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies.

Authors:  A Keppler-Hafkemeyer; R J Kreitman; I Pastan
Journal:  Int J Cancer       Date:  2000-07-01       Impact factor: 7.396

6.  The B cell coreceptor CD22 associates with AP50, a clathrin-coated pit adapter protein, via tyrosine-dependent interaction.

Authors:  BinuJoy John; Brantley R Herrin; Chander Raman; Yan-ni Wang; Kevin R Bobbitt; Brian A Brody; Louis B Justement
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

7.  Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact.

Authors:  Brian E Collins; Ola Blixt; Alexis R DeSieno; Nicolai Bovin; Jamey D Marth; James C Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

8.  Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.

Authors:  Joseph M Tuscano; Robert T O'Donnell; Laird A Miers; Linda A Kroger; David L Kukis; Kathleen R Lamborn; Thomas F Tedder; Gerald L DeNardo
Journal:  Blood       Date:  2003-01-02       Impact factor: 22.113

9.  Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins.

Authors:  Thomas Decker; Madlene Oelsner; Robert J Kreitman; Giuliana Salvatore; Qing-cheng Wang; Ira Pastan; Christian Peschel; Thomas Licht
Journal:  Blood       Date:  2003-10-02       Impact factor: 22.113

10.  Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signaling.

Authors:  Lei Jin; Paul A McLean; Benjamin G Neel; Henry H Wortis
Journal:  J Exp Med       Date:  2002-05-06       Impact factor: 14.307

View more
  43 in total

Review 1.  Siglecs as sensors of self in innate and adaptive immune responses.

Authors:  James C Paulson; Matthew S Macauley; Norihito Kawasaki
Journal:  Ann N Y Acad Sci       Date:  2012-01-30       Impact factor: 5.691

2.  Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain.

Authors:  Andrew T Vaughan; Claude H T Chan; Christian Klein; Martin J Glennie; Stephen A Beers; Mark S Cragg
Journal:  J Biol Chem       Date:  2015-01-07       Impact factor: 5.157

3.  Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells.

Authors:  Jeremy A O'Sullivan; Daniela J Carroll; Yun Cao; Adriano N Salicru; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2017-07-20       Impact factor: 10.793

4.  Tsg101 positively regulates physiologic-like cardiac hypertrophy through FIP3-mediated endosomal recycling of IGF-1R.

Authors:  Kobina Essandoh; Shan Deng; Xiaohong Wang; Min Jiang; Xingjiang Mu; Jiangtong Peng; Yutian Li; Tianqing Peng; Kay-Uwe Wagner; Jack Rubinstein; Guo-Chang Fan
Journal:  FASEB J       Date:  2019-03-18       Impact factor: 5.191

Review 5.  Siglec-mediated regulation of immune cell function in disease.

Authors:  Matthew S Macauley; Paul R Crocker; James C Paulson
Journal:  Nat Rev Immunol       Date:  2014-09-19       Impact factor: 53.106

6.  Disubstituted Sialic Acid Ligands Targeting Siglecs CD33 and CD22 Associated with Myeloid Leukaemias and B Cell Lymphomas.

Authors:  Cory D Rillahan; Matthew S Macauley; Erik Schwartz; Yuan He; Ryan McBride; Britni M Arlian; Janani Rangarajan; Valery V Fokin; James C Paulson
Journal:  Chem Sci       Date:  2014-06-01       Impact factor: 9.825

Review 7.  Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.

Authors:  Takumi Kiwamoto; Norihito Kawasaki; James C Paulson; Bruce S Bochner
Journal:  Pharmacol Ther       Date:  2012-06-27       Impact factor: 12.310

Review 8.  Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.

Authors:  Takashi Angata; Corwin M Nycholat; Matthew S Macauley
Journal:  Trends Pharmacol Sci       Date:  2015-10       Impact factor: 14.819

9.  Click and pick: identification of sialoside analogues for siglec-based cell targeting.

Authors:  Cory D Rillahan; Erik Schwartz; Ryan McBride; Valery V Fokin; James C Paulson
Journal:  Angew Chem Int Ed Engl       Date:  2012-10-04       Impact factor: 15.336

Review 10.  The Glycoscience of Immunity.

Authors:  Julie Y Zhou; Douglas M Oswald; Kelsey D Oliva; Lori S C Kreisman; Brian A Cobb
Journal:  Trends Immunol       Date:  2018-05-11       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.